Table 2 Mean utility scores among different socio-economic and clinical groups of indoor cancer patients in India
Sociodemographic Category | Sample size | Mean HRQoL score | VAS Score | ||
|---|---|---|---|---|---|
N (%) | Mean (95%CIs) | p-value* | Mean (95%CIs) | p-value* | |
Age groups (in years) | Â | Â | Â | Â | Â |
0–15 | 134 (5%) | 0.606 (0.535,0.677) | 0.003 | 55.03 (52.38,57.68) | 0.342 |
16–30 | 254 (9.5%) | 0.619 (0.573,0.666) | 56.54 (54.57,58.51) | ||
31–45 | 620 (23.3%) | 0.564 (0.537,0.591) | 55.16 (54.04,56.29) | ||
45–60 | 1039 (39.1%) | 0.54 (0.517,0.563) | 56.59 (55.69,57.49) | ||
Above 60 | 613 (23%) | 0.524 (0.495,0.554) | 55.96 (54.77,57.16) | ||
Gender | Â | Â | Â | Â | Â |
Male | 1470 (55.2%) | 0.551 (0.532,0.57) | 0.805 | 56.44 (55.7,57.19) | 0.112 |
Female | 1191 (44.8%) | 0.555 (0.533,0.576) | 55.52 (54.65,56.39) | ||
Area of Residence | Â | Â | Â | Â | Â |
Urban | 1080 (40.6%) | 0.572 (0.55,0.594) | 0.092 | 55.75 (54.83,56.66) | 0.001 |
Rural | 1536 (57.7%) | 0.54 (0.521,0.558) | 56 (55.27,56.72) | ||
Slum | 45 (1.7%) | 0.541 (0.445,0.637) | 63.99 (59.73,68.24) | ||
Education | Â | Â | Â | Â | Â |
No education | 471 (17.7%) | 0.463 (0.427,0.5) | < 0.001 | 57.44 (56.14,58.73) | < 0.01 |
Primary & Middle | 836 (31.4%) | 0.556 (0.531,0.582) | 55.03 (54.07,55.98) | ||
Up to Senior Secondary | 802 (30.2%) | 0.548 (0.523,0.573) | 54.82 (53.76,55.88) | ||
Graduation & above | 551 (20.7%) | 0.63 (0.602,0.658) | 58.1 (56.79,59.42) | ||
Wealth Quintile | Â | Â | Â | Â | Â |
Poorest | 506 (19%) | 0.567 (0.536,0.598) | 0.705 | 53.18 (51.92,54.44) | < 0.001 |
Poor | 547 (20.6%) | 0.558 (0.527,0.589) | 54.87 (53.64,56.11) | ||
Middle | 557 (20.9%) | 0.556 (0.527,0.586) | 56.37 (55.18,57.57) | ||
Rich | 546 (20.5%) | 0.547 (0.517,0.578) | 58.21 (57.08,59.34) | ||
Richest | 505 (19%) | 0.535 (0.498,0.571) | 57.4 (55.92,58.89) | ||
Marital Status | Â | Â | Â | Â | Â |
Unmarried | 318 (11.9%) | 0.639 (0.598,0.679) | < 0.001 | 56.72 (54.98,58.46) | 0.065 |
Married | 2110 (79.3%) | 0.547 (0.532,0.563) | 55.68 (55.05,56.3) | ||
Separated/Divorced | 22 (0.8%) | 0.511 (0.286,0.736) | 58.89 (49.78,68) | ||
Widow/Widower | 211 (7.9%) | 0.482 (0.426,0.538) | 58.21 (56.15,60.28) | ||
Type of hospital | Â | Â | Â | Â | Â |
Public | 858 (32.3%) | 0.379 (0.353,0.405) | < 0.001 | 62.36 (61.43,63.29) | < 0.001 |
Semi-Private | 1802 (67.7%) | 0.635 (0.62,0.651) | 53.01 (52.35,53.68) | ||
Duration of hospitalisation (days) | Â | Â | Â | Â | Â |
1 | 503 (18.9%) | 0.663 (0.645,0.68) | < 0.001 | 50.49 (49.44,51.54) | < 0.01 |
2 | 291 (10.9%) | 0.573 (0.528,0.618) | 64.24 (62.33,66.14) | ||
3 | 290 (10.9%) | 0.479 (0.434,0.524) | 61.72 (60.2,63.24) | ||
4 | 348 (13.1%) | 0.539 (0.498,0.58) | 56.81 (55.35,58.28) | ||
5 | 435 (16.4%) | 0.531 (0.495,0.567) | 55.2 (53.85,56.55) | ||
> 5 | 794 (29.8%) | 0.52 (0.491,0.549) | 54.57 (53.5,55.64) | ||
Type of cancer | Â | Â | Â | Â | Â |
Solid | 2406 (90.4%) | 0.56 (0.546,0.575) | 0.002 | 56.36 (55.78,56.95) | < 0.001 |
Haematological | 255 (9.6%) | 0.483 (0.427,0.539) | 52.88 (50.82,54.95) | ||
Type of treatment | Â | Â | Â | Â | Â |
Chemotherapy | 1646 (62.7%) | 0.587 (0.57,0.603) | < 0.001 | 57.37 (56.69,58.05) | < 0.001 |
Radiotherapy | 121 (4.6%) | 0.621 (0.561,0.681) | 54.65 (52.27,57.03) | ||
Palliative Care | 39 (1.5%) | 0.247 (0.122,0.372) | 50.23 (44.72,55.74) | ||
Surgery | 115 (4.4%) | 0.518 (0.444,0.593) | 57.99 (55.49,60.5) | ||
Combination therapy** | 231 (8.8%) | 0.413 (0.359,0.467) | 58.92 (56.91,60.93) | ||
Maintenance therapy | 16 (0.6%) | -0.276 (-0.425,-0.128) | 27.11 (18.35,35.88) | ||
Diagnostic | 110 (4.2%) | 0.451 (0.369,0.534) | 54.44 (51.21,57.68) | ||
Hormone Therapy | 3 (0.1%) | 0.488 (0.488,0.488) | 60 (60,60) | ||
Immunotherapy | 31 (1.2%) | 0.726 (0.675,0.777) | 51.31 (47.45,55.18) | ||
Others (clinical follow up) | 311 (11.9%) | 0.569 (0.527,0.611) | 50.3 (48.56,52.04) | ||
Cancer Stage | Â | Â | Â | Â | Â |
Carcinoma in Situ | 1 (0%) | 0.737 (0,0) | < 0.001 | 45 (0,0) | 0.462 |
Stage I | 83 (5%) | 0.638 (0.573,0.704) | 55.99 (52.36,59.62) | ||
Stage II | 283 (17%) | 0.677 (0.643,0.711) | 55.82 (54.3,57.33) | ||
Stage III | 599 (36%) | 0.609 (0.583,0.635) | 57.29 (56.02,58.56) | ||
Stage IV | 698 (41.9%) | 0.516 (0.489,0.543) | 56.07 (55.05,57.08) | ||
Response to Treatment | Â | Â | Â | Â | Â |
Disease Free | 237 (9.1%) | 0.553 (0.507,0.599) | < 0.001 | 53.36 (51.39,55.34) | 0.001 |
Progressive Disease | 131 (5%) | 0.42 (0.345,0.496) | 53.42 (50.42,56.43) | ||
Ongoing treatment* | 2233 (85.9%) | 0.561 (0.546,0.577) | 56.63 (56.02,57.24) | ||
Line to Treatment | Â | Â | Â | Â | Â |
First Line | 2270 (87.4%) | 0.572 (0.557,0.587) | < 0.001 | 56.33 (55.72,56.94) | 0.001 |
Second Line | 278 (10.7%) | 0.417 (0.368,0.467) | 55.51 (53.64,57.39) | ||
Third Line | 36 (1.4%) | 0.444 (0.308,0.579) | 55.64 (50.45,60.83) | ||
Fourth Line | 12 (0.5%) | 0.416 (0.268,0.565) | 39.27 (30.66,47.88) | ||
Adverse Effect | Â | Â | Â | Â | Â |
With Adverse Effect | 2097 (82.6%) | 0.544 (0.528,0.56) | < 0.001 | 56.55 (55.93,57.17) | 0.154 |
Without Adverse Effect | 440 (17.4%) | 0.637 (0.606,0.669) | 55.35 (53.83,56.88) | ||
Total | Â | 0.553 (0.539,0.567) | Â | 56.03 (55.46,56.6) | Â |